This is a StreetInsider.com Premium Only Page

Natera (NTRA) – Company Press Releases

Apr 22, 2024 08:00 AM Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications

Apr 11, 2024 08:00 AM Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation

Apr 8, 2024 08:00 AM Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients

Apr 5, 2024 07:00 AM Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer

Apr 1, 2024 08:00 AM Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer

Mar 18, 2024 07:00 AM Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer

Mar 14, 2024 08:00 AM New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease

Mar 12, 2024 08:00 AM Natera to Present New Data at the 2024 SGO Annual Meeting on Women’s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers

Mar 7, 2024 08:00 AM Natera Announces Commercial Coverage for Prospera™ Kidney and Prospera Heart™ from a Top BCBS Plan

Feb 29, 2024 08:00 AM Natera to Participate in March Investor Conferences

Feb 28, 2024 04:05 PM Natera Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 27, 2024 08:00 AM Natera Announces Next Phase of CareDx Patent Infringement Litigation Seeking Royalty For All Ongoing And Future AlloSure Tests

Feb 26, 2024 07:00 AM Medicare Extends Coverage of Natera’s Signatera™ MRD Test to Ovarian Cancer and Neoadjuvant Breast Cancer

Feb 20, 2024 08:00 AM Natera Announces Fourth Quarter and Fiscal 2023 Earnings Conference Call

Feb 5, 2024 08:00 AM New Study Validates Signatera™ in Endometrial Cancer

Jan 30, 2024 09:15 AM Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030

Jan 30, 2024 07:00 AM New Publication Demonstrates Signatera’s Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung Cancer

Jan 29, 2024 07:00 AM Jury Rules in Favor of Natera in Patent Infringement Lawsuit Against CareDx; Awards $96.3 Million in Damages to Natera in Lost Profits and Past Royalties

Jan 26, 2024 09:45 PM CareDx Issues Statement in Patent Infringement Case

Jan 25, 2024 07:00 AM Nature Medicine Publishes Two Studies Highlighting Signatera’s Clinical Utility in Patients with Gastrointestinal Malignancies

Jan 22, 2024 07:00 AM Invitae Completes Sale of Reproductive Health Assets to Natera

Jan 22, 2024 07:00 AM Natera Acquires Reproductive Health Assets from Invitae

Jan 18, 2024 08:00 AM Natera to Present New Data from the CIRCULATE-Japan and BESPOKE CRC Studies at ASCO GI 2024 Supporting Signatera’s Clinical Utility in CRC

Jan 16, 2024 05:17 PM Natera Provides Update on Ravgen Trial

Jan 9, 2024 07:00 AM Natera Announces Preliminary Fourth Quarter and Full Year 2023 Revenues

Dec 29, 2023 08:00 AM Natera to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Dec 27, 2023 11:48 PM Natera Wins Preliminary Injunction in Patent Infringement Lawsuit Against NeoGenomics’ RaDaR Test

Dec 21, 2023 08:00 AM Natera Announces New Study Highlighting the Benefits of Signatera’s Unique Method of Quantifying ctDNA

Dec 11, 2023 12:50 PM Delaware Court Denies CareDx’s Motion for Summary Judgment on Two Natera Patents

Dec 6, 2023 08:30 AM Natera Presents New Signatera™ MRD Data Across Breast Cancer Treatment Settings at SABCS 2023

Nov 14, 2023 08:00 AM Natera Announces Real-World Data Collaboration with Merck

Nov 8, 2023 04:05 PM Natera Reports Third Quarter 2023 Financial Results

Nov 8, 2023 09:10 AM Natera Announces Randomized, Phase III TREAT ctDNA Trial in Early-Stage Breast Cancer

Nov 7, 2023 08:30 AM Natera to Participate in November Investor Conferences

Nov 2, 2023 08:30 AM Natera’s Landmark RenaCARE Study Demonstrates Significant Diagnostic and Clinical Utility of Renasight™ in Chronic Kidney Disease

Oct 23, 2023 12:18 PM INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates Natera, Inc.’s Directors and Officers for Breach of Fiduciary Duties – NTRA

Oct 22, 2023 01:00 PM Updated Data from CIRCULATE-Japan Presented at ESMO 2023 Reinforces Signatera’s Prognostic and Predictive Value in Analysis of 2,500+ Colorectal Cancer Patients

Oct 20, 2023 09:00 AM Natera to Report its Third Quarter 2023 Results on November 8

Oct 19, 2023 09:00 AM Natera Recognized on U.S. News & World Report’s 2024 Best Companies to Work for in Healthcare Ranking

Oct 16, 2023 09:00 AM Natera to Present New Signatera™ MRD Data at ESMO 2023, Featuring Large, Updated Analysis from CIRCULATE-Japan Study

Oct 4, 2023 09:00 AM New MRD Publication in Unresectable Stage I-III Lung Cancer Demonstrates Signatera’s Ability to Risk Stratify and Detect Progression Early

Oct 3, 2023 04:43 PM Supreme Court Denies CareDx Request for Appeal in Patent Case with Natera

Oct 2, 2023 09:00 AM Natera Submits First PMA Module to the FDA for Signatera™

Sep 18, 2023 09:00 AM Natera Announces Senior Leadership Appointments

Sep 14, 2023 09:00 AM Natera Announces Expanded I-SPY 2 Collaboration to Evaluate Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting

Sep 7, 2023 12:09 AM Natera Announces Pricing of $250 Million Follow-On Offering

Sep 6, 2023 04:24 PM Natera Launches Proposed Follow-On Offering

Sep 1, 2023 09:00 AM Natera to Participate in Upcoming Investor Conferences

Aug 16, 2023 09:00 AM Natera’s Prospera™ Lung Transplant Assessment Test Granted Medicare Coverage

Aug 7, 2023 11:08 AM CareDx Announces District Court Judge Bars Natera from Falsely Advertising and Overstating the Scientific Performance of its Prospera Transplant Test